Drugs & Targets FDA publishes draft guidance on characterizing, collecting, and reporting immune-mediated adverse reactions October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on tissue agnostic drug development in oncology October 21, 2022Vol.48 No.38
Drugs & Targets Pluvicto receives positive CHMP opinion for prostate cancer October 21, 2022Vol.48 No.38
Drugs & Targets Libtayo receives positive CHMP opinion for advanced cervical cancer October 21, 2022Vol.48 No.38
Drugs & Targets HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers October 21, 2022Vol.48 No.38
Drugs & Targets Jazz Pharmaceuticals and Zymeworks agree to develop, commercialize zanidatamab October 21, 2022Vol.48 No.38
Drugs & Targets Health Canada approves Merck’s Keytruda as post-surgery monotherapy in kidney cancer patients October 14, 2022Vol.48 No.37
Drugs & Targets Eclipse and Mayo create Nucleus RadioPharma to improve radiopharmaceutical manufacturing October 14, 2022Vol.48 No.37
Drugs & Targets FDA grants accelerated approval to Lytgobi for cholangiocarcinoma October 07, 2022Vol.48 No.36
